MediciNova spikes on potential of lead asset in brain cancer [Seeking Alpha]
MediciNova, Inc. (MNOV)
Last medicinova, inc. earnings: 4/23 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
medicinova.com/investor-relations/media-archive
Company Research
Source: Seeking Alpha
Citing a recent data readout presented at a medical event in Canada, MediciNova ( MNOV ) said that 44% of new GBM patients who received MN-166 (ibudilast) with cancer medicine temozolomide (TMZ) remained alive without cancer progression (progression-free survival) at six months. The La Jolla, California-based biotech said the progression-free survival rate for recurrent GBM patients stood at 31%. As for safety, the drug combination was safe and well tolerated, with no unexpected adverse effects. The Phase 2 trial involved 36 newly diagnosed GBM patients and 26 recurrent GBM patients who received MN-166 plus temozolomide. As its primary goals, the investigators evaluated the drug combo's six-month PFS as well as safety and tolerability. The presentation also included preclinical data to suggest that MN-166, in combination with an anti-PD1 inhibitor, can extend survival in a mouse model with GBM. Recommended For You Recommended For You About MNOV Related Stocks Tr
Show less
Read more
Impact Snapshot
Event Time:
MNOV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNOV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNOV alerts
High impacting MediciNova, Inc. news events
Weekly update
A roundup of the hottest topics
MNOV
News
- MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.MarketBeat
- MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy [Yahoo! Finance]Yahoo! Finance
- MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral NeuropathyGlobeNewswire
- MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.MarketBeat
- MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MNDGlobeNewswire
MNOV
Earnings
- 11/12/25 - Beat
MNOV
Sec Filings
- 12/12/25 - Form EFFECT
- 12/5/25 - Form S-3
- 11/12/25 - Form 10-Q
- MNOV's page on the SEC website